EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Pharmacokinetics, Safety, and Tolerability of Different Maintenance Dose Regimens of Mosnodenvir (JNJ‐1802) in Healthy Adult Participants

Thomas N Kakuda, Nicole Harasym, Annemie Buelens, Ariane Kahnt, Caroline Feys, Ami Nilsson, Nele Goeyvaerts, Tristan Baguet, Tine De Marez, Guillermo Herrera-Taracena, Freya Rasschaert

Clinical Pharmacology in Drug Development · 2025

DOI: 10.1002/cpdd.1574 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Thomas N Kakuda und 10 weiteren Autor:innen. Beteiligte Einrichtung: Johnson & Johnson, San Diego, CA, USA. Hauptthemen laut MEDLINE: Antiviral Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dengue virus infection has become a global health concern, and no dengue‐specific treatment is available. Mosnodenvir is a pan‐serotypic dengue antiviral in clinical development. In this Phase 1, open‐label study (NCT05201937), high‐ and low‐dose weekly, and twice weekly maintenance doses (MDs) of mosnodenvir were evaluated following a twice daily loading dose (LD) over 2 days. The utility of a convenient capillary blood sampling device (TASSO‐M20) was also explored. Healthy adults were sequentially assigned to receive: 450 mg twice daily LD, 900 mg once weekly MD; 450 mg twice daily LD, 450 mg twice weekly MD; 150 mg twice daily LD, 300 mg once weekly MD; or 150 mg twice daily LD, 150 mg twice weekly MD. Mosnodenvir exposure rapidly increased with LD and was maintained during the MD phase. In general, mosnodenvir increased in a dose‐proportional manner with similar areas under the concentration‐time curve between once weekly and twice weekly MD. The mean terminal elimination half‐life across treatments was 6.7‐8.7 days, supporting less frequent dosing. Safety and tolerability were similar across all treatment regimens. TASSO‐M20 was preferred over venipuncture by participants. In summary, mosnodenvir administered weekly or biweekly achieved pharmacokinetic exposures that were found to be safe and well tolerated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHumansAdultMaleFemaleYoung AdultHealthy VolunteersMiddle AgedDrug Administration ScheduleDose-Response Relationship, DrugHalf-LifeArea Under CurveAdolescentHydrocarbons, HalogenatedIndoles

Stichwörter der Autor:innen

antiviraldenguemicrosamplingmosnodenvirpharmacokinetics

Substanzen

Antiviral AgentsJNJ-1802Hydrocarbons, HalogenatedIndoles

Autor:innen und Institutionen

  • Johnson & Johnson, San Diego, CA, USA.
  • Johnson & Johnson, Spring House, PA, USA.
  • Johnson & Johnson, Beerse, Belgium.
  • Johnson & Johnson, Leiden, the Netherlands.
  • Johnson & Johnson, Horsham, PA, USA.

Zitieren

APA

Kakuda, T. N., Harasym, N., Buelens, A., Kahnt, A., Feys, C., Nilsson, A., Goeyvaerts, N., Baguet, T., Marez, T., Herrera-Taracena, G., & Rasschaert, F. (2025). Pharmacokinetics, Safety, and Tolerability of Different Maintenance Dose Regimens of Mosnodenvir (JNJ‐1802) in Healthy Adult Participants. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1574

Vancouver

Kakuda TN, Harasym N, Buelens A, Kahnt A, Feys C, Nilsson A, et al. Pharmacokinetics, Safety, and Tolerability of Different Maintenance Dose Regimens of Mosnodenvir (JNJ‐1802) in Healthy Adult Participants. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1574

BibTeX
@article{Kakuda2025,
  author = {Kakuda, Thomas N and Harasym, Nicole and Buelens, Annemie and Kahnt, Ariane and Feys, Caroline and Nilsson, Ami and Goeyvaerts, Nele and Baguet, Tristan and Marez, Tine De and Herrera-Taracena, Guillermo and Rasschaert, Freya},
  title = {Pharmacokinetics, Safety, and Tolerability of Different Maintenance Dose Regimens of Mosnodenvir (JNJ‐1802) in Healthy Adult Participants},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  doi = {10.1002/cpdd.1574}
}
Kostenlos starten →